Curasight A/S reports positive preclinical results with uTREAT[®] in aggressive brain cancer (glioblastoma)
· Preclinical studies show uTREAT[®] efffective in treating aggressive brain cancer · Data supports strategy to move uTREAT[®] into clinical development for evaluation in patients with aggressive brain cancer Copenhagen, June 7, 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) is pleased to announce preclinical data demonstrating the effectiveness of uTREAT[®] in treating aggressive brain cancer (glioblastoma). The results from the study validate Curasight's strategic focus on developing uTREAT[®] as a viable treatment option for patients with aggressive brain cancer.